Breaking News

Tweet TWEET

Abbott Announces Pricing of AbbVie's $14.7 Billion Private Placement Notes Offering

  Abbott Announces Pricing of AbbVie's $14.7 Billion Private Placement Notes
                                   Offering

  PR Newswire

  ABBOTT PARK, Illinois, Nov. 6, 2012

ABBOTT PARK, Illinois, Nov. 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT)
announced today that its wholly-owned subsidiary, AbbVie Inc., priced the
private placement offering launched on Nov. 5, 2012, of $3.5 billion of 1.20%
senior notes due 2015 (the "2015 Notes"), $4 billion of 1.75% senior notes due
2017 (the "2017 Notes"), $1 billion of 2.00% senior notes due 2018 (the "2018
Notes"), $3.1 billion of 2.90% senior notes due 2022 (the "2022 Notes"), $2.6
billion of 4.40% senior notes due 2042 (the "2042 Notes"), and $500 million of
floating rate senior notes due 2015 (the "Floating Rate Notes," and, together
with the 2015 Notes, the 2017 Notes, the 2018 Notes, the 2022 Notes and the
2042 Notes, the "Notes"). The closing of the offering is expected to occur on
Nov. 8, 2012, subject to customary closing conditions.

Interest on the 2015 Notes, the 2017 Notes, the 2018 Notes, the 2022 Notes and
the 2042 Notes will be payable semiannually, in cash in arrears, on May 6 and
Nov. 6 of each year, commencing on May 6, 2013. Interest on the Floating Rate
Notes will be payable quarterly, in cash in arrears, on Feb. 6, May 6, Aug. 6
and Nov. 6 of each year, commencing on Feb. 6, 2013. Each series of Notes
initially will be guaranteed on an unsecured, unsubordinated basis by Abbott.
Each of the Abbott guarantees will terminate upon the distribution of shares
of AbbVie common stock to Abbott shareholders. AbbVie intends to use the net
proceeds from the sale of the Notes (other than the 2022 Notes, which will be
sold by a selling noteholder) to make a cash distribution to Abbott, to pay
related fees and expenses and for general corporate purposes. Abbott intends
to use the proceeds it receives from AbbVie, in part, to fund its previously
announced cash tender offers for certain of Abbott's outstanding notes.

The Notes are being offered only to qualified institutional buyers in reliance
on Rule 144A under the Securities Act of 1933, as amended (the "Securities
Act"), and outside the United States, only to non-U.S. investors pursuant to
Regulation S under the Securities Act. The Notes will not be initially
registered under the Securities Act or any state securities laws and may not
be offered or sold in the United States absent an effective registration
statement or an applicable exemption from registration requirements or a
transaction not subject to the registration requirements of the Securities Act
or any state securities laws.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any security and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offering, solicitation
or sale would be unlawful. Any offers of the Notes will be made only by means
of a private offering memorandum.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery,
development, manufacturing and marketing of pharmaceuticals and medical
products, including nutritionals, devices and diagnostics. The company employs
approximately 91,000 people and markets its products in more than 130
countries.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning
Forward-Looking Statements

Statements made in this news release contain forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of the
Securities and Exchange Act of 1934, as amended, including, without
limitation, statements related to our future growth, trends in our industry,
our financial or operational results, our financial or operational performance
and the planned separation of Abbott's research-based pharmaceutical company
from its diversified medical products company and the expected financial
results of Abbott and AbbVie after the separation. Such forward-looking
statements are predictive in nature, and may be based on current expectations,
forecasts or assumptions involving risks and uncertainties that could cause
actual outcomes and results to differ materially from the forward-looking
statements themselves. Such forward-looking statements may, without
limitation, be preceded by, followed by, or include words such as "believes,"
"expects," "anticipates," "estimates," "intends," "plans," "seeks,"
"forecasts" or similar expressions, or may employ such future or conditional
verbs as "may," "will," "should" or "would" or may otherwise be indicated as
forward-looking statements by grammatical construction, phrasing or context.
For those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the U.S. Private Securities Litigation
Reform Act of 1995.

Forward-looking statements are not guarantees of future performance. Economic,
competitive, governmental, technological and other factors that may affect
Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual
Report on Securities and Exchange Commission Form 10-K for the year ended Dec.
31, 2011.

Except as required by applicable law, Abbott disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Abbott may not update
these forward-looking statements, even if its situation changes in the future.
All forward-looking statements attributable to Abbott are expressly qualified
by these cautionary statements.

Website: http://www.abbott.com
Contact: Scott Stoffel, +1-847-936-9502